Immuneering Corporation Stock-Based Compensation
Immuneering Corporation (IMRX) reported Stock-Based Compensation of $3.26 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-05
- Immuneering Corporation share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $1.63M, a 6.75% increase year-over-year.
- Immuneering Corporation share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $1.64M, a 3.29% decline year-over-year.
- Immuneering Corporation share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.64M, a 5.04% decline year-over-year.
- Immuneering Corporation share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.46M, a 11.22% decline year-over-year.
- Immuneering Corporation share-based payment arrangement, noncash expense for fiscal 2025 was $6.31M, a 2.93% decline from fiscal 2024.
- Immuneering Corporation share-based payment arrangement, noncash expense for fiscal 2024 was $6.50M, a 13.52% increase from fiscal 2023.
- Immuneering Corporation share-based payment arrangement, noncash expense for fiscal 2023 was $5.73M, a 40.91% increase from fiscal 2022.
- Immuneering Corporation share-based payment arrangement, noncash expense for fiscal 2022 was $4.06M, a 125.47% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $3.26M 10-Q · filed 2026-08-05 | $4.90M derived: sum of 3 quarters · filed 2026-08-05 | $6.36M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $1.64M 10-Q · filed 2026-05-15 | $3.27M derived: sum of 2 quarters · filed 2026-05-15 | $4.73M derived: sum of 3 quarters · filed 2026-05-15 | $6.26M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $3.09M derived: sum of 2 quarters · filed 2026-03-06 | $4.62M derived: sum of 3 quarters · filed 2026-08-05 | $6.31M 10-K · filed 2026-03-06 |
| 2025-09-30 | $1.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.98M derived: sum of 2 quarters · filed 2026-08-05 | $4.67M 10-Q · filed 2025-11-12 | $6.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $3.22M 10-Q · filed 2026-08-05 | $4.94M derived: sum of 3 quarters · filed 2026-08-05 | $6.58M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.69M 10-Q · filed 2026-05-15 | $3.42M derived: sum of 2 quarters · filed 2026-05-15 | $5.06M derived: sum of 3 quarters · filed 2026-05-15 | $6.72M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $3.36M derived: sum of 2 quarters · filed 2026-03-06 | $5.03M derived: sum of 3 quarters · filed 2026-03-06 | $6.50M 10-K · filed 2026-03-06 |
| 2024-09-30 | $1.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $3.30M derived: sum of 2 quarters · filed 2025-11-12 | $4.78M 10-Q · filed 2025-11-12 | $6.42M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $3.14M 10-Q · filed 2025-08-13 | $4.78M derived: sum of 3 quarters · filed 2025-08-13 | $6.26M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $1.47M 10-Q · filed 2025-05-05 | $3.12M derived: sum of 2 quarters · filed 2025-05-05 | $4.59M derived: sum of 3 quarters · filed 2025-05-05 | $5.93M derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $3.12M derived: sum of 2 quarters · filed 2025-03-20 | $4.45M derived: sum of 3 quarters · filed 2025-03-20 | $5.73M 10-K · filed 2025-03-20 |
| 2023-09-30 | $1.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $2.81M derived: sum of 2 quarters · filed 2024-11-13 | $4.09M 10-Q · filed 2024-11-13 | $5.13M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $1.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $2.61M 10-Q · filed 2024-08-06 | $3.66M derived: sum of 3 quarters · filed 2024-08-06 | $4.72M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $1.27M 10-Q · filed 2024-05-07 | $2.32M derived: sum of 2 quarters · filed 2024-05-07 | $3.39M derived: sum of 3 quarters · filed 2024-05-07 | $4.44M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $2.11M derived: sum of 2 quarters · filed 2024-03-01 | $3.17M derived: sum of 3 quarters · filed 2024-03-01 | $4.06M 10-K · filed 2024-03-01 |
| 2022-09-30 | $1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $2.12M derived: sum of 2 quarters · filed 2023-11-09 | $3.02M 10-Q · filed 2023-11-09 | $3.65M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $1.95M 10-Q · filed 2023-08-03 | $2.58M derived: sum of 3 quarters · filed 2023-08-03 | $3.22M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $897.65K 10-Q · filed 2023-05-04 | $1.53M derived: sum of 2 quarters · filed 2023-05-04 | $2.17M derived: sum of 3 quarters · filed 2023-05-04 | $2.52M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $632.58K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $1.27M derived: sum of 2 quarters · filed 2023-03-06 | $1.62M derived: sum of 3 quarters · filed 2023-03-06 | $1.80M 10-K · filed 2023-03-06 |
| 2021-09-30 | $636.81K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $987.82K derived: sum of 2 quarters · filed 2022-11-10 | $1.17M 10-Q · filed 2022-11-10 | $1.39M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $351.01K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $533.23K 10-Q · filed 2022-08-10 | $749.84K derived: sum of 3 quarters · filed 2022-08-10 | $1.06M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $182.22K 10-Q · filed 2022-05-10 | $398.83K derived: sum of 2 quarters · filed 2022-05-10 | $709.30K derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | $216.61K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $527.07K derived: sum of 2 quarters · filed 2022-03-10 | $1.09M 10-K · filed 2022-03-10 | |
| 2020-09-30 | $310.46K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $870.16K 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $559.70K 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |